Compare SHIP & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHIP | PRLD |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.9M | 391.1M |
| IPO Year | 2008 | 2020 |
| Metric | SHIP | PRLD |
|---|---|---|
| Price | $16.92 | $4.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $17.00 | $5.67 |
| AVG Volume (30 Days) | 276.1K | ★ 329.7K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $20.07 | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $13.34 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $7.21 | $0.75 |
| 52 Week High | $18.48 | $5.69 |
| Indicator | SHIP | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 54.95 |
| Support Level | $13.60 | $3.92 |
| Resistance Level | N/A | $4.69 |
| Average True Range (ATR) | 0.79 | 0.33 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 72.20 | 65.94 |
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through a modern fleet of Capesize vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Blueship, Meiship, Kaizenship, Iconship, Titanship, Flagship, Paroship, Worldship, Hellasship, Partnership, Championship, Patriotship, Dukeship, Honorship, Fellowship, Knightship, Lordship, Premiership, Squireship, and Friendship.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.